Suicide Gene Therapy

Nonhuman Primate Study Suggests Intracerebral Suicide Gene Therapy Feasible

Published in Gene Therapy Weekly, November 2nd, 1998

Results from a toxicity study in nonhuman primates suggest that the intracerebral injection of an adenovirus harboring the herpes simplex virus thymidine kinase (HSVtk) gene, followed by ganciclovir (GCV) administration, should be feasible in humans.

Several studies have demonstrated that in vivo administration of adenovirus to the brain and visceral organs can induce an inflammatory reaction. Therefore, the use of adenoviral vectors in clinical gene therapy may be limited by toxic effects to surrounding normal tissue.

To address these questions before initiating a phase I clinical trial in human glioma patients, M.J. Driesse and colleagues from the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-11-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry